Ad
Search
Generic filters
Filter by content type
Taxonomy terms

ALZN – Alzamend Neuro Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 11.25

Low: 7.5

High: 15

Total Analysts: 2

Company Profile

Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of Alzheimer’s disease (Alzheimer’s), bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company’s pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). The Company’s AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses